Trade Regenxbio Inc - RGNX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 16 |
| Open | 15.69 |
| 1-Year Change | -17.94% |
| Day's Range | 15.32 - 16.08 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 16.03 | 0.40 | 2.56% | 15.63 | 16.12 | 15.14 |
| Apr 24, 2024 | 16.00 | 0.16 | 1.01% | 15.84 | 16.02 | 15.55 |
| Apr 23, 2024 | 15.85 | 0.34 | 2.19% | 15.51 | 16.25 | 15.46 |
| Apr 22, 2024 | 15.61 | -0.15 | -0.95% | 15.76 | 16.05 | 15.14 |
| Apr 19, 2024 | 15.64 | -0.33 | -2.07% | 15.97 | 16.23 | 15.27 |
| Apr 18, 2024 | 16.05 | -0.62 | -3.72% | 16.67 | 16.77 | 16.01 |
| Apr 17, 2024 | 16.99 | -0.56 | -3.19% | 17.55 | 17.58 | 16.96 |
| Apr 16, 2024 | 17.45 | -0.07 | -0.40% | 17.52 | 18.18 | 17.43 |
| Apr 15, 2024 | 17.98 | 0.01 | 0.06% | 17.97 | 18.57 | 17.78 |
| Apr 12, 2024 | 18.07 | -0.34 | -1.85% | 18.41 | 19.22 | 17.59 |
| Apr 11, 2024 | 18.99 | 0.65 | 3.54% | 18.34 | 19.03 | 18.34 |
| Apr 10, 2024 | 18.81 | 0.66 | 3.64% | 18.15 | 18.99 | 18.15 |
| Apr 9, 2024 | 18.97 | 0.19 | 1.01% | 18.78 | 19.67 | 18.69 |
| Apr 8, 2024 | 19.16 | 0.02 | 0.10% | 19.14 | 19.30 | 18.77 |
| Apr 5, 2024 | 19.14 | 0.40 | 2.13% | 18.74 | 19.80 | 18.47 |
| Apr 4, 2024 | 19.11 | -1.17 | -5.77% | 20.28 | 20.69 | 19.03 |
| Apr 3, 2024 | 20.19 | 0.22 | 1.10% | 19.97 | 20.59 | 19.78 |
| Apr 2, 2024 | 20.23 | -0.76 | -3.62% | 20.99 | 21.01 | 20.13 |
| Apr 1, 2024 | 21.50 | 0.73 | 3.51% | 20.77 | 21.51 | 20.49 |
| Mar 28, 2024 | 21.00 | -1.12 | -5.06% | 22.12 | 22.13 | 20.90 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Regenxbio Inc Company profile
About Regenxbio Inc
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates use adeno-associated virus (AAV) vectors from its gene delivery platform, called NAV Technology Platform. Its product candidate includes RGX-314, RGX-111, RGX-121, RGX-202, RGX 181 and RGX-381. RGX-314 is meant for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) and other anti-VEGF treated conditions. It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II). RGX-202 is its product candidate for the treatment of duchenne muscular dystrophy (DMD).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Regenxbio Inc revenues increased from $154.6M to $470.3M. Net income totaled $127.8M vs. loss of $111.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Foreign Exchange Gain/Loss–Non-Business decrease from $8M (expense) to $2.2M (income).
| Industry: | Bio Therapeutic Drugs |
9804 Medical Center Drive
ROCKVILLE
MARYLAND 20850
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com